- Home
- GGAL vs AXSM Comparison
GGAL vs AXSM Comparison
Compare GGAL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | AXSM |
|---|---|---|
| Founded | 1905 | 2012 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 9.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | GGAL | AXSM |
|---|---|---|
| Price | $43.08 | $154.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | $69.00 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 1.2M | 472.6K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.56 | $58.34 |
| Revenue Next Year | $17.81 | $54.30 |
| P/E Ratio | $13.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $86.99 |
| 52 Week High | $66.24 | $191.50 |
Technical Indicators
Market Signals| Indicator | GGAL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 30.40 |
| Support Level | $25.97 | $148.14 |
| Resistance Level | $54.05 | $191.13 |
| Average True Range (ATR) | 2.00 | 5.49 |
| MACD | 0.03 | -1.32 |
| Stochastic Oscillator | 24.75 | 6.36 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.